(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for "screening" drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).
Contents:
1. Biologic and Technical Considerations for the Design of Screening Procedures for the Assessment of Biological Response Modifiers.- 2. Procedures for Preclinical Screening of Biological Response Modifying Agents.- 3. Preclinical Evaluation of Individual Biological Response Modifiers.- 4. Clinical Correlations.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: November, 2011
Pages: 212
Weight: 332g
Availability: Available
Subcategories: Oncology
From the same series
Dirk J. Ruiter
R. Verley
H.F. Seigler
Kenneth V. Honn
Franco M. Muggia
P. Hilgard
Noburo Kobayashi
James M. Church
L. Dogliotti
A. Giacosa
Seymour Garte
John Masters
Kintomo Takakura
B.A. Stoll
J. Mark Elwood
Laurence H. Baker
Laurence H. Baker
George D. Demetri
B.A. Stoll
A. Giacosa
Franco M. Muggia
Matthew J. van Zwieten
L.A. Liotta
Kenneth A. Foon
P.I. Reed
Paul H. Sugarbaker
Gabriel A. Kune
Frederick A. Valeriote
R. Ceriani
B. Lowenberg
D.G. Poplack
J. Bánóczy
Thomas R. Tritton
Miles P. Hacker
Aaron Polliack
B. Lowenberg
Pelayo Correa
Alexander H.G. Paterson
Franco M. Muggia
J. Aisner
Stephen T. Sonis
F.J. Cleton
Kenneth V. Honn
Stephen T. Sonis
Soldano Ferrone
Stephen B Howell
C.C. Tijssen
B.W. Hancock
B.W. Ongerboer de Visser
A.P.M. Heintz
B.A. Stoll
A.M. Ward
Daniel L. Kisner
Marvin A. Rich
J. Gordon McVie
J.R. Ryan
Marvin A. Rich
Kenneth V. Honn
D.G. Poplack
Anthony J. Mastromarino
Frederick A. Valeriote
Marvin A. Rich
Laurence H. Baker
P.K. Pattengale
G.B. Snow
Frederick A. Valeriote